Notice of Cipher Pharmaceuticals Q1 2011 Conference Call and 2010 Annual & Special Meeting of Shareholders

Toronto Stock Exchange Symbol: DND

MISSISSAUGA, ON, May 5 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) today announced it will host a conference call for its Q1 2011 financial results and hold an Annual & Special Meeting of Shareholders on Thursday, May 12, 2011.

Q1 2011 CONFERENCE CALL

WHEN:  THURSDAY, MAY 12, 2011 AT 8:30 A.M. ET

CONFERENCE CALL / WEBCAST:  You can join the call by dialling 647-427-7450 or 1-888-231-8191. A live audio webcast will be available through http://www.cipherpharma.com or http://www.newswire.ca. An archived replay of the webcast will be available for 365 days.

ANNUAL & SPECIAL MEETING OF SHAREHOLDERS

WHEN:            Thursday, May 12, 2011 at 11:00 A.m. ET.
WHERE:      

Toronto Board of Trade
1 First Canadian Place
Toronto, Ontario

WEBCAST: The meeting will be webcast live. To access the webcast go to www.cipherpharma.com or http://www.newswire.ca.  Please connect at least 15 minutes prior to the start of the meeting to ensure adequate time for any software download that may be required to join the webcast. An archived replay of the webcast will be available for 365 days.

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals is a commercial-stage drug development company focused on commercializing novel formulations of successful, currently marketed molecules using advanced drug delivery technologies. Cipher's strategy is to in-license products that incorporate proven drug delivery technologies and advance them through the clinical development and regulatory approval stages, after which the products are out-licensed to international partners. Because Cipher's products are based on proven technology platforms applied to currently marketed drugs, they are expected to have lower approval risk, shorter development timelines and significantly lower development costs. The Company's lead compound is being marketed in the United States by Kowa Pharmaceuticals America under the label Lipofen®. Cipher's second product, an extended-release version of the pain reliever tramadol, received FDA approval in May 2010 and the Company's third product, a novel formulation of the acne treatment isotretinoin, is in its final Phase III safety study.

Cipher is listed on the Toronto Stock Exchange under the symbol 'DND' and has approximately 24 million shares outstanding.  For more information, please visit www.cipherpharma.com.

SOURCE Cipher Pharmaceuticals Inc.

For further information:

Craig Armitage      
Investor Relations     
The Equicom Group     
(416) 815-0700 ext 278     
(416) 815-0080 fax     
carmitage@equicomgroup.com  
              Larry Andrews
President and CEO
Cipher Pharmaceuticals
(905) 602-5840 ext 324
(905) 602-0628 fax
landrews@cipherpharma.com


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.